March #21 : Cocktail Hour - by Walter Armstrong and Ronnilyn Pustil

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Larry Kramer Gets Angry

Radiant Radical

Adventures in Brain Chemistry

Cackles, Cauldrons, and Carrots

Johnny Appleseed

The Way To a Man's Heart

Tools of the Trade

Life Imitates Art

S.O.S.-March 1997

Mailbox-March 1997

Notes of a Native Son

Out in the Cold

Cocktail Hour

Gallo's Humor

Vanity Unfair

Uh-Oh, Canada

Dental Damns

School for Scandal

"Provide" Services

Goes Around, Comes Around

Whatever Happened to Mary Jane

The Buddy Line

Rebel YELL

Bull's Eye

Body at Work

Alive and Kicking

ACTing UP All Over

All in Good Time

Tabling the Situation

POZ Picks-March 1997

ACT UP's First Days

5,985 and Counting

A Specific Point of View

Dead Gorgeous

Sex and the Single Positoid

Misplaced Lust

The Anger Channel

Dose of Reality

Feeling Blue? Much to Do!

Kicking Butt

Expand Your Medicine Cabinet

Wean on Me

Feeling Queasy? Help is Easy

The Right Stuff

A Load Off His Mind

Carbo Diem

Monkey Business

Taking Action

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

March 1997

Cocktail Hour

by Walter Armstrong and Ronnilyn Pustil

Activists cry, "Put up your nukes!"

For those excluded from the miracle of protease cocktails, there's good and bad news. The good news-Glaxo Wellcome's new nucleoside blockbuster, abacavir, or 1592, is right around the corner. The bad news? According to The Wall Street Journal, that corner is at least a year and a half away.

The skinny on abacavir, which has been in the pipeline for seven years, was too hot to keep secret. It's said to be 10 times more potent than AZT, without all the nasty side effects.

Activists charge Glaxo with major foot-dragging in an effort to protect the sales of AZT and 3TC, the drug's nuke cousins. The combined AZT/3TC revenue is expected to hit $600 million this year and could exceed $1 billion by 1998. The drug giant hit paydirt as thousands of patients rush to build a "cocktail" regimen, starting with AZT/3TC and adding one of the antiprotease drugs. But no one is likely to choose either nuke over the virile young abacavir. Because abacavir will be combined with other drugs in "cocktail" therapy, Glaxo says the safety trials will take at least 18 months. Fair enough, say activists. Meantime, they demand Glaxo make abacavir available for "compassionate use."

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.